19 October 2022  
EMA/838787/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Comirnaty 
tozinameran 
On 19 October 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Comirnaty. The marketing authorisation holder for this medicinal product is BioNTech Manufacturing 
GmbH. 
The CHMP adopted an extension to an existing indication to include use of Comirnaty 3 micrograms/dose 
in children from 6 months of age. The full indication for Comirnaty 3 micrograms/dose will be as follows: 
Comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for 
active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children 
aged 6 months to 4 years.  
The use of this vaccine should be in accordance with official recommendations. 
For information, the indications for other compositions of the vaccine are provided in the Summary of 
Product Characteristics for Comirnaty. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union  
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
